Rejected at 5:57 p.m. Mar, 25, 2025 ] by mitchelnelson
Author: madelsmur
Related Note: 1503254970225
Rationale for change

"On the basis of recent clinical trial data for the treatment of drug-susceptible and drug-resistant tuberculosis (TB), the American Thoracic Society, U.S. Centers for Disease Control and Prevention, European Respiratory Society, and Infectious Diseases Society of America have updated clinical practice guidelines for TB treatment in children and adults in settings in which mycobacterial cultures, molecular and phenotypic drug susceptibility tests, and radiographic studies, among other diagnostic tools, are available on a routine basis." They now recommend a "4-month regimen of isoniazid, rifapentine, moxifloxacin, and pyrazinamide" for new active TB.
Source: Society Guidelines - https://www.atsjournals.org/doi/full/10.1164/rccm.202410-2096ST

Rejection reason

Please resubmit with an acceptable source. Please review suggestion guidelines, specifically rule #1: 📚 AnKing Step Deck Submission Guidelines

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize

Physeo









OME
Additional Resources


One by one
Empty field
#PANCE::PULM::infectious_disorders #AK_Step1_v12::#AMBOSS::pNaLXO #AK_Step2_v12::#UWorld::COMLEX::104297 #AK_Step1_v12::#Pixorize::04_Microbiology::06_Bacteria-Gram_Indeterminate::02_Mycobacterium_tuberculosis:_Disease_(TB) !AK_UpdateTags::Step1decks::Lolnotacop::Bugs #AK_Step1_v12::#Physeo::09_Pharm::05_Antibiotics::23_Isoniazid_(RIPE) #AK_Step2_v12::#Resources_by_rotation::IM::uw::renal::renal_dorian #AK_Step1_v12::#OME_banner::Basic_Science::12_Renal #AK_Step1_v12::^Other::^HighYield::1-HighYield #PANCE::EOR::Family_med #AK_Step1_v12::#Physeo::09_Pharm::05_Antibiotics::22_Dapsone,_Rifamycins,_Clofazimine_(Leprosy_Drugs) #AK_Step1_v12::#SketchyPharm::07_Antimicrobials::03_Antimycobacterials::01_Tuberculosis_Drugs #AK_Step1_v12::#Bootcamp::Microbiology::08_Mycobacteria::04_Pulmonary_Tuberculosis_Diagnostics_And_Management #AK_Step1_v12::#FirstAid::03_Microbiology::07_Antimicrobials::26_Antituberculous_drugs::*Isoniazid #AK_Step1_v12::#FirstAid::03_Microbiology::07_Antimicrobials::26_Antituberculous_drugs::*Ethambutol #AK_Step1_v12::#Physeo::09_Pharm::05_Antibiotics::24_Ethambutol_&_Pyrazinamide #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Original_Decks::Step_1::Lolnotacop::Bugs #AK_Step1_v12::#Bootcamp::Microbiology::36_Antibiotics::24_Pyrazinamide_Ethambutol_Dapsone_and_Clofazimine #AK_Step1_v12::#FirstAid::03_Microbiology::07_Antimicrobials::26_Antituberculous_drugs::*Rifamycins #AK_Step1_v12::#Bootcamp::Microbiology::36_Antibiotics::22_Isoniazid #AK_Step1_v12::#OME_banner #AK_Step1_v12::#FirstAid::03_Microbiology::07_Antimicrobials::26_Antituberculous_drugs::*Pyrazinamide #AK_Step1_v12::#Bootcamp::Microbiology::33_Infectious_Neuropathology::04_Atypical_Meningoencephalitis #AK_Step1_v12::#Physeo::06_Micro::02_Bacteria::41_Mycobacterium_Tuberculosis #AK_Step2_v12::Original_decks::Zanki_Step_2::IM::Renal #AK_Step1_v12::#SketchyMicro::01_Bacteria::08_Mycobacteria::01_Mycobacterium_Tuberculosis #AK_Step2_v12::#UWorld::Step::19425 #AK_Step1_v12::#FirstAid::03_Microbiology::02_Clinical_Bacteriology::20_Tuberculosis #AK_Step2_v12::#Resources_by_rotation::IM::uw::renal::renal_zanki #AK_Step2_v12::!Shelf::IM::no_dupes #AK_Step2_v12::Original_decks::Dorian::im::uw::renal #AK_Other::Card_Features::^One_By_One #AK_Step1_v12::#FirstAid::03_Microbiology::02_Clinical_Bacteriology::19_Mycobacteria::*Mycobacterium_Tuberculosis